A Plus Biotechnology Co., Ltd. (TPE:6918)
Taiwan
· Delayed Price · Currency is TWD 81.50
-2.50 (-2.98%)
At close: Mar 9, 2026
A Plus Biotechnology Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 825.52 | 769.59 | 675.05 | 541.85 | 503.29 |
| Revenue Growth (YoY) | 11.83% | 14.01% | 24.58% | 7.66% | - |
| Cost of Revenue | 251.55 | 234.81 | 214.37 | 195.46 | 185.36 |
| Gross Profit | 573.97 | 534.78 | 460.67 | 346.39 | 317.93 |
| Selling, General & Admin | 319.04 | 299.15 | 233.43 | 237.16 | 203.12 |
| Research & Development | 45.26 | 53.34 | 59.54 | 63.08 | 79.96 |
| Operating Expenses | 364.3 | 352.32 | 293.13 | 299.65 | 275.4 |
| Operating Income | 209.67 | 182.46 | 167.54 | 46.74 | 42.53 |
| Interest Expense | -2.17 | -2.19 | -2.69 | -2.2 | -1.19 |
| Interest & Investment Income | 2.81 | 2.27 | 1.71 | 0.42 | 2.05 |
| Currency Exchange Gain (Loss) | -0.01 | 1.68 | 0.03 | - | - |
| Other Non Operating Income (Expenses) | 0.57 | 3.35 | -163.59 | 1.1 | 4.36 |
| EBT Excluding Unusual Items | 212.86 | 187.57 | 3 | 46.06 | 47.75 |
| Gain (Loss) on Sale of Assets | -0 | -0.01 | - | - | - |
| Other Unusual Items | 0.02 | - | 0.04 | - | - |
| Pretax Income | 212.87 | 187.56 | 3.04 | 46.06 | 47.75 |
| Income Tax Expense | 41.21 | 36.5 | 14.34 | 10.43 | 8.71 |
| Earnings From Continuing Operations | 171.66 | 151.06 | -11.31 | 35.63 | 39.04 |
| Minority Interest in Earnings | -0.12 | - | - | -2.69 | -2.97 |
| Net Income | 171.54 | 151.06 | -11.31 | 32.94 | 36.06 |
| Net Income to Common | 171.54 | 151.06 | -11.31 | 32.94 | 36.06 |
| Net Income Growth | 1135.00% | - | - | -8.66% | - |
| Shares Outstanding (Basic) | 32 | 30 | 30 | 29 | 29 |
| Shares Outstanding (Diluted) | 32 | 30 | 30 | 29 | 29 |
| Shares Change (YoY) | 5.53% | 0.37% | 4.70% | 0.95% | - |
| EPS (Basic) | 5.40 | 4.99 | -0.37 | 1.15 | 1.26 |
| EPS (Diluted) | 5.38 | 4.97 | -0.37 | 1.14 | 1.26 |
| EPS Growth | 1069.88% | - | - | -9.52% | - |
| Free Cash Flow | 145.39 | 152.09 | 149.72 | -168.55 | 107.35 |
| Free Cash Flow Per Share | 4.56 | 5.01 | 4.95 | -5.83 | 3.75 |
| Dividend Per Share | 4.000 | 4.000 | 0.900 | - | - |
| Dividend Growth | 344.44% | 344.44% | - | - | - |
| Gross Margin | 69.53% | 69.49% | 68.24% | 63.93% | 63.17% |
| Operating Margin | 25.40% | 23.71% | 24.82% | 8.63% | 8.45% |
| Profit Margin | 20.78% | 19.63% | -1.68% | 6.08% | 7.17% |
| Free Cash Flow Margin | 17.61% | 19.76% | 22.18% | -31.11% | 21.33% |
| EBITDA | 225.07 | 197.32 | 181.35 | 68.17 | 68.01 |
| EBITDA Margin | 27.27% | 25.64% | 26.86% | 12.58% | 13.51% |
| D&A For EBITDA | 15.4 | 14.86 | 13.81 | 21.43 | 25.48 |
| EBIT | 209.67 | 182.46 | 167.54 | 46.74 | 42.53 |
| EBIT Margin | 25.40% | 23.71% | 24.82% | 8.63% | 8.45% |
| Effective Tax Rate | 19.36% | 19.46% | 472.12% | 22.64% | 18.24% |
Source: S&P Capital IQ. Standard template. Financial Sources.